U.S. Markets closed

Investors Who Bought Iovance Biotherapeutics (NASDAQ:IOVA) Shares Three Years Ago Are Now Up 173%

Simply Wall St

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. To wit, the Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) share price has flown 173% in the last three years. That sort of return is as solid as granite. Also pleasing for shareholders was the 64% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

View our latest analysis for Iovance Biotherapeutics

With zero revenue generated over twelve months, we don't think that Iovance Biotherapeutics has proved its business plan yet. As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. It seems likely some shareholders believe that Iovance Biotherapeutics has the funding to invent a new product before too long.

Companies that lack both meaningful revenue and profits are usually considered high risk. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt. Of course, if you time it right, high risk investments like this can really pay off, as Iovance Biotherapeutics investors might know.

When it last reported its balance sheet in March 2019, Iovance Biotherapeutics could boast a strong position, with cash in excess of all liabilities of US$413m. That allows management to focus on growing the business, and not worry too much about raising capital. And given that the share price has shot up 40% per year, over 3 years, its fair to say investors are liking management's vision for the future. The image below shows how Iovance Biotherapeutics's balance sheet has changed over time; if you want to see the precise values, simply click on the image.

NasdaqGM:IOVA Historical Debt, May 22nd 2019

In reality it's hard to have much certainty when valuing a business that has neither revenue or profit. Given that situation, many of the best investors like to check if insiders have been buying shares. If they are buying a significant amount of shares, that's certainly a good thing. Luckily we are in a position to provide you with this free chart of insider buying (and selling).

A Different Perspective

Iovance Biotherapeutics shareholders are down 1.8% for the year, but the market itself is up 4.8%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 20% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.